A phase 3, open-label, randomized study to evaluate the efficacy and safety of single-agent belantamab mafodotin (belamaf) compared to pomalidomide plus low-dose dexamethasone (Pd) in patients (pts) with relapsed/refractory multiple myeloma (RRMM): DREAMM-3
| Title: | A phase 3, open-label, randomized study to evaluate the efficacy and safety of single-agent belantamab mafodotin (belamaf) compared to pomalidomide plus low-dose dexamethasone (Pd) in patients (pts) with relapsed/refractory multiple myeloma (RRMM): DREAMM-3 |
|---|---|
| Authors: | Weisel, Katja1 (AUTHOR), Hungria, Vania TM2 (AUTHOR), Radinoff, Atanas3 (AUTHOR), Delimpasi, Sosana4 (AUTHOR), Mikala, Gabor5 (AUTHOR), Masszi, Tamas6 (AUTHOR), Li, Jian7 (AUTHOR), Capra, Marcelo8 (AUTHOR), Matsumoto, Morio9 (AUTHOR), Sule, Neal10 (AUTHOR), Li, Mary10 (AUTHOR), McKeown, Astrid11 (AUTHOR), He, Wei12 (AUTHOR), Bright, Shelley10 (AUTHOR), Currie, Brooke13 (AUTHOR), Boyle, Julia14 (AUTHOR), Opalinska, Joanna10 (AUTHOR), Dimopoulos, Meletios A.15 (AUTHOR) |
| Source: | Journal of Clinical Oncology. 2023 Supplement 16, Vol. 41, p8007-8007. 1p. |
| Database: | Supplemental Index |
| ISSN: | 0732183X |
|---|---|
| DOI: | 10.1200/JCO.2023.41.16_suppl.8007 |
| Published in: | Journal of Clinical Oncology |
| Language: | English |